Identification and Preclinical Pharmacology of Theγ-Secretase Modulator BMS-869780

International Journal of Alzheimer's Disease - United States
doi 10.1155/2014/431858
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials

English

Discovery and Preclinical Evaluation of BMS-955829 a Potent Positive Allosteric Modulator of mGluR5

English

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable Γ-Secretase Inhibitor

ACS Medicinal Chemistry Letters
Organic ChemistryBiochemistryDrug Discovery
2010English

Synthetic Antidiarrheal Drugs Synthesis Preclinical and Clinical Pharmacology

Gut
Gastroenterology
1976English

APLP1 as a Cerebrospinal Fluid Biomarker for Γ-Secretase Modulator Treatment

Alzheimer's Research and Therapy
NeurologyCognitive Neuroscience
2015English

Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug

Journal of Pharmacology and Experimental Therapeutics
Molecular MedicinePharmacology
2017English

A Γ-Secretase Inhibitor, but Not a Γ-Secretase Modulator, Induced Defects in BDNF Axonal Trafficking and Signaling: Evidence for a Role for APP

PLoS ONE
Multidisciplinary
2015English

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Preclinical Antitumor Activity of BMS-599626, a Pan-Her Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

Clinical Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy